Bryn Mawr Trust Advisors LLC Has $26.75 Million Stock Holdings in Merck & Co., Inc. $MRK

Bryn Mawr Trust Advisors LLC trimmed its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 3.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 222,405 shares of the company's stock after selling 8,169 shares during the period. Merck & Co., Inc. accounts for approximately 1.3% of Bryn Mawr Trust Advisors LLC's holdings, making the stock its 12th largest position. Bryn Mawr Trust Advisors LLC's holdings in Merck & Co., Inc. were worth $26,753,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. in the fourth quarter worth $26,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. during the fourth quarter worth $26,000. High Note Wealth LLC increased its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after buying an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on MRK shares. UBS Group boosted their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. Citigroup assumed coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price objective on the stock. BMO Capital Markets raised their price objective on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a research note on Monday. JPMorgan Chase & Co. raised their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday. Finally, Scotiabank boosted their target price on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $133.94.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA expanded approval for Merck’s Keytruda, in combination with Pfizer’s Padcev, for use in muscle-invasive bladder cancer regardless of cisplatin eligibility, potentially expanding the market opportunity for one of Merck’s most important cancer drugs. FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer
• Positive Sentiment: JPMorgan, BMO Capital Markets, and Guggenheim all raised their price targets on Merck and maintained bullish ratings, signaling improved Wall Street confidence in MRK’s upside. Analyst price target updates
• Positive Sentiment: Commentary highlighting Merck as a bargain and the stock’s recent attention in the S&P 500 focus list may be adding to investor optimism around the shares. Merck (MRK) Stock Looks Like A Bargain At This Price
• Neutral Sentiment: There was also discussion of Merck’s Januvia/Janumet franchise as a benchmark in a generic drug partnership story, but this appears to be more contextual than a direct new catalyst for MRK today. Cosmos Health Accelerates Prescription Medicine Strategy...
• Negative Sentiment: Retail chatter continues to focus on Merck’s looming Keytruda patent cliff, which remains a longer-term risk even as near-term news flow is positive. SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout...

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $123.93 on Tuesday. The company has a market capitalization of $306.09 billion, a PE ratio of 34.91, a price-to-earnings-growth ratio of 2.65 and a beta of 0.19. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $130.29. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company's fifty day moving average price is $119.12 and its 200 day moving average price is $116.50.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the previous year, the business earned $2.22 EPS. The business's revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.'s payout ratio is currently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.